Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP COSTA-SILVA, Thais Alves da
LINDOSO, Jose Angelo Lauletta FMUSP-HC
BARBOSA, Leandro R. S.
TEMPONE, Andre Gustavo 2017
dc.identifier.citation ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v.61, n.4, article ID UNSP e02297, 15p, 2017
dc.identifier.issn 0066-4804
dc.description.abstract Visceral leishmaniasis is a fatal parasitic neglected disease affecting 1.5 million people worldwide. Based on a drug repositioning approach, the aim of this work was to investigate the in vitro immunomodulatory potential of buparvaquone (BPQ) and to establish a safe regimen to evaluate the in vivo efficacy of BPQ entrapped by negatively charged nanoliposomes (BPQ-LP) in Leishmania infantum-infected hamsters. Small-angle X-ray scattering, dynamic light scattering, and the zeta-potential were applied in order to study the influence of BPQ on the liposome structure. Our data revealed that BPQ was located in the polar-apolar interface, snorkeling the polar region, and protected against aggregation inside the lipophilic region. The presence of BPQ also decreased the Z-average hydrodynamic diameter and increased the surface charge. Compared to intravenous and intramuscular administration, a subcutaneous route was a more effective route for BPQ-LP; at 0.4 mg/kg, BPQ-LP reduced infection in the spleen and liver by 98 and 96%, respectively. Treatment for 5 days resulted in limited efficacy, but 10 days of treatment resulted in an efficacy similar to that of a 15-day regimen. The nanoliposomal drug was highly effective, with a mean 50% effective dose of 0.25 mg/kg, reducing the parasite load in bone marrow by 80%, as detected using quantitative PCR analysis. In addition, flow cytometry studies showed that BPQ upregulated cytokines as tumor necrosis factor, monocyte chemoattractant protein 1, interleukin-10 (IL-10), and IL-6 in Leishmania-infected macrophages, eliminating the parasites via a nitric oxide-independent mechanism. This new formulation proved to be a safe and effective treatment for murine leishmaniasis that could be a useful candidate against visceral leishmaniasis.
dc.description.sponsorship · CNPq
· GlaxoSmithKline
· Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/23403-9, 2015/15822-1, 2013/07275-5, 2013/50228-8]
dc.language.iso eng
dc.relation.ispartof Antimicrobial Agents and Chemotherapy
dc.rights restrictedAccess
dc.subject Leishmania; drug delivery; liposomes; therapy
dc.subject.other visceral leishmaniasis; cutaneous leishmaniasis; mice lacking; bone-marrow; l. chagasi; in-vitro; liposomes; donovani; size; phagocytosis
dc.title Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model
dc.type article
dc.rights.holder Copyright AMER SOC MICROBIOLOGY LIM/49 LIM/38
dc.identifier.doi 10.1128/AAC.02297-16
dc.identifier.pmid 28167544
dc.type.category original article
dc.type.version publishedVersion GALISTEO JR., Andres Jimenez:HC:LIM/49 LINDOSO, Jose Angelo Lauletta:HC:LIM/38 · COSTA-SILVA, Thais Alves da:Adolfo Lutz Inst, Ctr Parasitol & Mycol, Sao Paulo, Brazil
· BARBOSA, Leandro R. S.:Univ Sao Paulo, Inst Fis, Sao Paulo, Brazil
· TEMPONE, Andre Gustavo:Adolfo Lutz Inst, Ctr Parasitol & Mycol, Sao Paulo, Brazil 2-s2.0-85017034589 WOS:000397598800042 WASHINGTON USA
hcfmusp.relation.reference · ALLEN TM, 1993, BIOCHIM BIOPHYS ACTA, V1150, P9, DOI 10.1016/0005-2736(93)90115-G
· Binker MG, 2007, J IMMUNOL, V179, P3780
· Boerman OC, 1997, J NUCL MED, V38, P489
· Burza S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002603
· Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
· Colombo FA, 2011, PARASITOL RES, V109, P267, DOI 10.1007/s00436-010-2247-6
· Cotterell SEJ, 1999, EUR J IMMUNOL, V29, P203, DOI 10.1002/(SICI)1521-4141(199901)29:01<203::AID-IMMU203>3.0.CO;2-B
· Croft SL, 1996, J ANTIMICROB CHEMOTH, V38, P1041, DOI 10.1093/jac/38.6.1041
· CROFT SL, 1992, J ANTIMICROB CHEMOTH, V30, P827, DOI 10.1093/jac/30.6.827
· de Mello CX, 2016, AM J TROP MED HYG, V99, P99
· Dey R, 2007, SCAND J IMMUNOL, V66, P671, DOI 10.1111/j.1365-3083.2007.02025.x
· Dhanikula Anand Babu, 2005, Current Drug Delivery, V2, P35, DOI 10.2174/1567201052772852
· Domingues MM, 2013, BBA-BIOMEMBRANES, V1828, P2419, DOI 10.1016/j.bbamem.2013.06.009
· Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016
· Fernandez RM, 2008, BBA-BIOMEMBRANES, V1778, P907, DOI 10.1016/j.bbamem.2007.12.005
· Johnston MJW, 2008, J LIPOSOME RES, V18, P145, DOI 10.1080/08982100802129372
· Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
· Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x
· Kedzierski L, 2006, PARASITOLOGY, V133, pS87, DOI 10.1017/S0031182006001831
· Kolodziej H, 2005, PHYTOCHEMISTRY, V66, P2056, DOI 10.1061/j.phytochem.2005.01.011
· LAMY L, 1966, Bulletin de la Societe de Pathologie Exotique, V59, P964
· Lezama-Davila CM, 2008, IMMUNOL CELL BIOL, V86, P539, DOI 10.1038/icb.2008.39
· Li H, 2011, ARCH PHARM RES, V34, P941, DOI 10.1007/s12272-011-0611-4
· Maia C, 2012, J TROP MED, V2012, DOI 10.1155/2012/541571
· McGwire BS, 2014, QJM-INT J MED, V107, P7, DOI 10.1093/qjmed/hct116
· Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135
· Monteiro N, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0459
· Muniz-Junqueira MI, 2008, INT IMMUNOPHARMACOL, V8, P1633, DOI 10.1016/j.intimp.2008.07.011
· Nashleanas M, 1998, J IMMUNOL, V160, P5506
· Ong SG, 2016, PHARMACEUTICS, V26
· Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
· Park HM, 2008, J COLLOID INTERF SCI, V317, P631, DOI 10.1016/j.jcis.2007.09.027
· Reimao JQ, 2012, EXP PARASITOL, V130, P195, DOI 10.1016/j.exppara.2012.01.010
· Reimao JQ, 2011, EXP PARASITOL, V128, P111, DOI 10.1016/j.exppara.2011.02.021
· ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0
· Rozenfeld JHK, 2015, PHYS CHEM CHEM PHYS, V17, P7498, DOI 10.1039/c4cp05652c
· Sanderson L, 2014, J ANTIMICROB CHEMOTH, V69, P1888, DOI 10.1093/jac/dku069
· Schettini DA, 2006, INT J PHARM, V315, P140, DOI 10.1016/j.ijpharm.2006.01.048
· Sou K, 2007, BIOMATERIALS, V28, P2655, DOI 10.1016/j.biomaterials.2007.01.041
· Spinozzi F, 2014, J APPL CRYSTALLOGR, V47, P1132, DOI 10.1107/S1600576714005147
· STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9
· Swamydas M, 2013, JOVE-J VIS EXP, V10
· Tardi P, 2016, J DRUG TARGET, V16, P1
· Tempone AG, 2004, J ANTIMICROB CHEMOTH, V54, P60, DOI 10.1093/jac/dkh281
· Tempone AG, 2010, INT J ANTIMICROB AG, V36, P159, DOI 10.1016/j.ijantimicag.2010.04.006
· Tiuman TS, 2011, INT J INFECT DIS, V15, pE525, DOI 10.1016/j.ijid.2011.03.021
· Torres DC, 2010, INFECT GENET EVOL, V10, P727, DOI 10.1016/j.meegid.2010.05.006
· Tuladhar R, 2011, INT J BIOL SCI, V7, P1382
· Vexenat JA, 1998, VET PARASITOL, V77, P71, DOI 10.1016/S0304-4017(96)01150-8
· World Health Organization,, 2016, LEISHM FACT SHEET
· Yamaguchi A, 2000, THROMB RES, V97, P317, DOI 10.1016/S0049-3848(99)00179-6
· Yap GS, 1998, J IMMUNOL, V160, P1340
· Yardley V, 2000, INT J ANTIMICROB AG, V13, P243, DOI 10.1016/S0924-8579(99)00133-8
dc.description.index MEDLINE
dc.identifier.eissn 1098-6596
hcfmusp.citation.scopus 3
hcfmusp.citation.wos 3

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account